Special Issue "Genomic Medicine and Advances in Vaccine Technology and Development in the Developing and Developed World"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (15 May 2020) | Viewed by 172794
Interests: antiaging research; anti-aging genes; appetite; environment; nutrition; senescence
Special Issues, Collections and Topics in MDPI journals
The market for vaccines is expected to reach 50 billion dollars by the year 2020. The development process for vaccine development from research to marketing may take 10 years and cost approx 1 billion dollars but the success rate of vaccine development may be very low. Critical interest in research to maintain vaccines that enhance the immune response to prevent diseases has been the focus of vaccine development. WHO funded vaccine preventable conditions and disease projects may only be successful with effective low calorie nutrigenomic diets that activate anti-aging gene expression critical to maintain the primary and secondary immune response in man and other species. In the developing world increasing therapeutic anti-aging protein levels in the plasma and cells has become important to maintain the immune system with relevance to vaccine technology. Biotherapy, core body temperature and anti-aging gene activation with relevance to the chronic disease epidemic is critical to prevent mitophagy and autoimmune disease linked to the prevention of inactivation of vaccines and vaccine development. Articles for this special issue are required to assess the role of anti-aging genes and activation of the transcriptional co-activator relevant to the adaptive immune response that determines the success of old and new vaccine development.
Dr Ian James Martins
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Genomic medicine
- vaccine development
- anti-aging genes
- transcriptional regulator
- autoimmune disease
- developing world
- immune response
- anti-aging protein